Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials

Executive Summary

FDA's Oncologic Drugs Advisory Committee will review products with unfulfilled accelerated approval postmarketing commitments during an upcoming meeting
Advertisement

Related Content

“Exceptional” Approval Could Replace “Accelerated” For Rare Cancer Drugs
“Exceptional” Approval Could Replace “Accelerated” For Rare Cancer Drugs
Accelerated approval Phase IV commitments
Accelerated approval Phase IV commitments
FDA Takes More Conservative Approach To Quantifying Oncologic Benefit
FDA Takes More Conservative Approach To Quantifying Oncologic Benefit
Accelerated Approval Status Disclosure Would Be Mandated By Markey Bill
Iressa Casts Shadow Over Zarnestra Advisory Committee Review
Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says
Cancer Drug Confirmatory Trials Should Be Initiated Early, FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS046363

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel